Actively Recruiting
TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography
Led by Norwegian University of Science and Technology · Updated on 2025-06-06
250
Participants Needed
1
Research Sites
146 weeks
Total Duration
On this page
Sponsors
N
Norwegian University of Science and Technology
Lead Sponsor
S
St. Olavs Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD). Secondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.
CONDITIONS
Official Title
TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Breast cancer and referral for follow-up to identify potential CTRCD
You will not qualify if you...
- Not willing or able to consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
St. Olavs hospital
Trondheim, Norway, 7491
Actively Recruiting
Research Team
E
Espen Holte, MD. PhD
CONTACT
H
Havard Dalen, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here